BIOMAT Database Logo BIOMAT Database Logo

Characterization and selective inhibition of myristoyl-CoA:protein N-myristoyltransferase from Trypanosoma brucei and Leishmania major. 2006

Chrysoula Panethymitaki, and Paul W Bowyer, and Helen P Price, and Robin J Leatherbarrow, and Katherine A Brown, and Deborah F Smith
Wellcome Trust Laboratories for Molecular Parasitology, Imperial College London, London SW7 2AZ, UK.

The eukaryotic enzyme NMT (myristoyl-CoA:protein N-myristoyltransferase) has been characterized in a range of species from Saccharomyces cerevisiae to Homo sapiens. NMT is essential for viability in a number of human pathogens, including the fungi Candida albicans and Cryptococcus neoformans, and the parasitic protozoa Leishmania major and Trypanosoma brucei. We have purified the Leishmania and T. brucei NMTs as active recombinant proteins and carried out kinetic analyses with their essential fatty acid donor, myristoyl-CoA and specific peptide substrates. A number of inhibitory compounds that target NMT in fungal species have been tested against the parasite enzymes in vitro and against live parasites in vivo. Two of these compounds inhibit TbNMT with IC50 values of <1 microM and are also active against mammalian parasite stages, with ED50 (the effective dose that allows 50% cell growth) values of 16-66 microM and low toxicity to murine macrophages. These results suggest that targeting NMT could be a valid approach for the development of chemotherapeutic agents against infectious diseases including African sleeping sickness and Nagana.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D000217 Acyltransferases Enzymes from the transferase class that catalyze the transfer of acyl groups from donor to acceptor, forming either esters or amides. (From Enzyme Nomenclature 1992) EC 2.3. Acyltransferase
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014346 Trypanosoma brucei brucei A hemoflagellate subspecies of parasitic protozoa that causes nagana in domestic and game animals in Africa. It apparently does not infect humans. It is transmitted by bites of tsetse flies (Glossina). Trypanosoma brucei,Trypanosoma brucei bruceus,Trypanosoma bruceus,brucei brucei, Trypanosoma,brucei, Trypanosoma brucei,bruceus, Trypanosoma,bruceus, Trypanosoma brucei
D018320 Leishmania major A parasitic hemoflagellate of the subgenus Leishmania leishmania that infects man and animals and causes cutaneous leishmaniasis (LEISHMANIASIS, CUTANEOUS) of the Old World. Transmission is by Phlebotomus sandflies. Leishmania (Leishmania) major,Leishmania tropica major,Leishmania leishmania major,Leishmania leishmania majors,Leishmania majors,Leishmania tropica majors,leishmania major, Leishmania,major, Leishmania leishmania,majors, Leishmania,majors, Leishmania leishmania,majors, Leishmania tropica,tropica major, Leishmania,tropica majors, Leishmania

Related Publications

Chrysoula Panethymitaki, and Paul W Bowyer, and Helen P Price, and Robin J Leatherbarrow, and Katherine A Brown, and Deborah F Smith
Purification and characterization of yeast myristoyl CoA:protein N-myristoyltransferase.
May 1987, Proceedings of the National Academy of Sciences of the United States of America,
Chrysoula Panethymitaki, and Paul W Bowyer, and Helen P Price, and Robin J Leatherbarrow, and Katherine A Brown, and Deborah F Smith
Synthesis and characterization of inhibitors of myristoyl-CoA:protein N-myristoyltransferase.
January 1991, Biochemical pharmacology,
Chrysoula Panethymitaki, and Paul W Bowyer, and Helen P Price, and Robin J Leatherbarrow, and Katherine A Brown, and Deborah F Smith
The structure of myristoyl-CoA:protein N-myristoyltransferase.
November 1999, Biochimica et biophysica acta,
Chrysoula Panethymitaki, and Paul W Bowyer, and Helen P Price, and Robin J Leatherbarrow, and Katherine A Brown, and Deborah F Smith
Preparation and assay of myristoyl-CoA:protein N-myristoyltransferase.
January 1999, Methods in molecular biology (Clifton, N.J.),
Chrysoula Panethymitaki, and Paul W Bowyer, and Helen P Price, and Robin J Leatherbarrow, and Katherine A Brown, and Deborah F Smith
Biochemical characterization of bovine brain myristoyl-CoA:protein N-myristoyltransferase type 2.
January 2009, Journal of biomedicine & biotechnology,
Chrysoula Panethymitaki, and Paul W Bowyer, and Helen P Price, and Robin J Leatherbarrow, and Katherine A Brown, and Deborah F Smith
Molecular cloning and biochemical characterization of bovine spleen myristoyl CoA:protein N-myristoyltransferase.
December 1997, Archives of biochemistry and biophysics,
Chrysoula Panethymitaki, and Paul W Bowyer, and Helen P Price, and Robin J Leatherbarrow, and Katherine A Brown, and Deborah F Smith
Synthesis of myristoyl CoA analogues and myristoyl peptides as inhibitors of myristoyl CoA:protein N-myristoyltransferase.
February 1994, Journal of pharmaceutical sciences,
Chrysoula Panethymitaki, and Paul W Bowyer, and Helen P Price, and Robin J Leatherbarrow, and Katherine A Brown, and Deborah F Smith
Molecular cloning, genomic organization, and biochemical characterization of myristoyl-CoA:protein N-myristoyltransferase from Arabidopsis thaliana.
March 2000, The Journal of biological chemistry,
Chrysoula Panethymitaki, and Paul W Bowyer, and Helen P Price, and Robin J Leatherbarrow, and Katherine A Brown, and Deborah F Smith
Purification and partial sequencing of myristoyl-CoA:protein N-myristoyltransferase from bovine brain.
March 1993, The Biochemical journal,
Chrysoula Panethymitaki, and Paul W Bowyer, and Helen P Price, and Robin J Leatherbarrow, and Katherine A Brown, and Deborah F Smith
A continuous assay of myristoyl-CoA:protein N-myristoyltransferase for proteomic analysis.
November 2003, Analytical biochemistry,
Copied contents to your clipboard!